Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Lilly

Stock Market Powers Higher On Microsoft, Meta, Trump Tariff Hopes: Weekly Review

The stock market rallied for the week, with the S&P 500 and Nasdaq clearing key levels, led by Microsoft and Meta as well as Trump tariff hopes.

Investors Business Daily

Eli Lilly Bounces Back. Zepbound Taking A Back Seat To Novo Nordisk's Wegovy At CVS.

Eli Lilly Bounces Back. Zepbound Taking A Back Seat To Novo Nordisk's Wegovy At CVS.

Eli Lilly bounces back on strong Q1 despite losing key battle in weight-loss drugs.

Investors Business Daily

2 ‘Strong Buy’ Stocks to Buy on Plans to Increase American Manufacturing

2 ‘Strong Buy’ Stocks to Buy on Plans to Increase American Manufacturing

Two checkered names from diverse industries are looking to bolster their manufacturing capabilities in the U.S. Here's how they stack up as investment ideas.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Eli Lilly Nails Oral GLP-1 Trial—Here’s What It Means for LLY

Take a deep dive into Eli Lilly's latest clinical GLP-1 results that sent shares soaring. The company has a big opportunity to serve needle-phobic patients.

Novo Nordisk Pops After Leapfrogging Eli Lilly With An Obesity Pill

Novo Nordisk stock popped Tuesday on reports it's asked the FDA to approve its weight-loss pill, an oral version of Wegovy.

Investors Business Daily

Eli Lilly's Quarterly Earnings Preview: What You Need to Know

Eli Lilly is scheduled to report its first-quarter results next month, and analysts expect a significant double-digit earnings growth.

Goldman Sachs Just Upgraded This Blue-Chip Stock. Should You Buy It Now?

With a strong pipeline, this pharmaceutical powerhouse is positioning itself as a dominant force in the future of medicine.

inkl

Read news from The Economist, FT, and more,
with one subscription

Ozempic in a pill? New oral drug may work as well as Ozempic-style injectables

Ozempic in a pill? New oral drug may work as well as Ozempic-style injectables

The drugmaker Lilly announced topline results of a clinical trial of a new pill in the same drug class as injectables like Ozempic.

Stock Market Tumbles On Nvidia Export Curbs, Fed Chief Powell, UnitedHealth: Weekly Review

Stock Market Tumbles On Nvidia Export Curbs, Fed Chief Powell, UnitedHealth: Weekly Review

The stock market sold off this week, with Nvidia AI chip export curbs, UnitedHealth guidance and Fed chief Jerome Powell's comments in focus.

Investors Business Daily

Experimental daily pill found to aid weight loss in what could be alternative to jabs like Ozempic

Experimental daily pill found to aid weight loss in what could be alternative to jabs like Ozempic

Other weight loss drugs must be injected, meaning the new pill from pharmaceutical giant Eli Lilly could become patients’ top choice if it is approved.

Eli Lilly Rockets 14% After Solidifying Its Lead For A Weight-Loss Pill

Eli Lilly Rockets 14% After Solidifying Its Lead For A Weight-Loss Pill

Eli Lilly stock jetted higher Thursday after the company said its diabetes and weight-loss pill helped patients lose up to 16 pounds.

Investors Business Daily

Hims’ Weight Loss Expansion: Real Growth or Just Hype?

Hims’ Weight Loss Expansion: Real Growth or Just Hype?

Will Hims and Hers' addition of Eli Lilly's Zepbound to its weight loss platform be a big new growth driver? Or, is this development all bark and no bite?

These 7 Stocks Are Analyst Favorites For Magnificent Earnings Growth; Arista, GE Lead

These 7 Stocks Are Analyst Favorites For Magnificent Earnings Growth; Arista, GE Lead

Among the best stocks in earnings performance, Broadcom boasts a 98 EPS Rating, one of the highest in the chip sector.

Investors Business Daily

Hims Claws Back After Its Lilly-Rivaling Obesity Plan Faces An Unexpected Hitch

Hims Claws Back After Its Lilly-Rivaling Obesity Plan Faces An Unexpected Hitch

Hims stock clawed higher Wednesday though analysts laid out low expectations for Him & Hers' branded tirzepatide.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Hims Stock Jumps After Adding Eli Lilly's Obesity Drug To Its Platform

Hims stock surged Tuesday after the compounding pharmacy said it would sell Eli Lilly's branded weight-loss drug on its telehealth platform.

Experimental Drug Shows Promise In Eliminating Hard-To-Treat Deadly Cholesterol

A single dose of lepodisiran dramatically lowered dangerous lipoprotein(a) levels for up to a year, offering new hope for heart disease treatment.

The Independent UK

European committee says Lilly Alzheimer's drug shouldn't get marketing approval

A European regulatory committee has rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially dangerous risks of brain bleeding and swelling

Price Targets Show These 3 Stocks Near the $1 Trillion Mark

See what analysts' price targets say about the prospects of these three stocks flirting with the $1 trillion valuation mark.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Novo Nordisk Finds A New Way To Rival Eli Lilly. But Shares Tumble.

Novo Nordisk stock dropped Monday after the drugmaker licensed a Chinese competitor's weight-loss drug for $200 million up front.

Is Viking Therapeutics the Next Blockbuster GLP-1 Stock?

Viking Therapeutic may have a GLP-1 blockbuster on their hands with VK2735 as it produces weight loss at 5X the speed of Novo Nordisk's Wegovy GLP-1 drug.

Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors

Novo Nordisk slashed prices on its GLP-1 obesity drugs as it launches NovoCare to gain compounded GLP-1 users as the compounding labs face deadlines to cease.

Eli Lilly Pours $27B Into U.S. Growth—What It Means for Investors

Pharma giant Eli Lilly announced plans to make a massive investment in the United States. What does this and another big announcement mean for Lilly?

Novo Nordisk Shares Near New 52-Week Low: Analysts See Big Upside

Novo Nordisk shares are closing in on a new 52-week low. Is the stock gearing up for a recovery with sentiment currently low?

Will Eli Lilly Stock Keep Climbing? Q2 Trial Results Are Crucial

Eli Lilly is still seeing rapid sales growth for its diabetes and weight loss drugs. However, one drug waiting in the wings hopes to be its next blockbuster.

Meet the 24-year-old helping Lilly test a preventive Alzheimer’s drug

Children who inherit genetic mutations from parents with early-onset Alzheimer’s typically show signs of dementia at the same age their parents did.

People

134,271 stories

Mark Zuckerberg

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

The New York Times

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Alzheimer Disease

Places

295,950 stories

The United States

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play